EUVIMEDEUVIMED entdecken
Crossref

Diagnostic Utility of a 90-Gene Expression Assay (Canhelp-Origin) for Patients with Metastatic Cancer with an Unclear or Unknown Diagnosis

Peng Qi iD, Yifeng Sun, Yue Pang, Jing Liu, Xu Cai, Shenglin Huang, Qinghua Xu, Qifeng Wang, Xiaoyan Zhou

Molecular Diagnosis & Therapy · 2025

DOI: 10.1007/s40291-024-00746-6 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Diagnosis & Therapy, 2025. Verfasst von Peng Qi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Fudan University Shanghai Cancer Center, Fudan University, No. 270 Dongan Road, Shanghai, 200032, People's Republic of China. Hauptthemen laut MEDLINE: Gene Expression Profiling, Neoplasms, Neoplasms, Unknown Primary, Biomarkers, Tumor. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Metastatic cancers with unclear or unknown origins pose significant challenges in diagnosis and management, frequently leading to suboptimal outcomes. Studies have demonstrated that a 90-gene expression assay is effective in predicting the primary origin and guiding the site-specific therapy to improve prognosis. This study aimed to evaluate the clinical effectiveness of a 90-gene expression assay in patients with unclear or unknown diagnoses. METHODS: The study encompassed patients for whom a 90-gene expression assay was requested as part of standard care. Data on patient demographics, tumor characteristics, and clinical history were collected. The assay's performance was evaluated by comparing its predicted tumor type with the final histopathological diagnosis. RESULTS: Among 303 cases analyzed, a 90-gene expression assay successfully identified a molecular-based tumor type for 295 (97.4%) patients. Comparison with histopathological diagnosis revealed an overall agreement of 88.5% (170/192). In patients with a single suspected primary site (n = 140), the assay confirmed the suspected diagnosis in 90.7% of cases. For those with a differential diagnosis (n = 52), the assay narrowed down the possibilities in 82.7% of cases. Moreover, in cases where the histopathology report indicated cancer of unknown primary (n = 103), the assay offered a molecular tumor type prediction with potential clinical significance. CONCLUSIONS: This study demonstrates the significant impact of a 90-gene expression assay on diagnosis and potential treatment selection for difficult-to-diagnose patients, highlighting its clinical value as a standardized molecular approach to streamline further diagnostic testing for patients with metastatic cancer of unclear or unknown origin. Further prospective study is required to assess whether employing molecular diagnostic classifiers enhances clinical outcomes in these patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gene Expression ProfilingNeoplasmsNeoplasms, Unknown PrimaryBiomarkers, TumorGene Expression Regulation, NeoplasticHumansFemaleMaleMiddle AgedNeoplasm MetastasisAgedAdultPrognosisDiagnosis, DifferentialAged, 80 and over

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Department of Pathology, Fudan University Shanghai Cancer Center, Fudan University, No. 270 Dongan Road, Shanghai, 200032, People's Republic of China.
  • Department of Oncology, Shanghai Medical College, Fudan University, No. 270 Dongan Road, Shanghai, 200032, People's Republic of China.
  • Shanghai Key Laboratory of Medical Epigenetics, Institutes of Biomedical Sciences, Fudan University, Shanghai, 200032, People's Republic of China.
  • Canhelp Genomics Research Center, Canhelp Genomics Co., Ltd., No.22 Xinyan Road, Hangzhou, 310000, People's Republic of China.
  • Canhelp Genomics Research Center, Canhelp Genomics Co., Ltd., No.22 Xinyan Road, Hangzhou, 310000, People's Republic of China. qinghua.xu@canhelpgenomics.com.
  • Department of Pathology, Fudan University Shanghai Cancer Center, Fudan University, No. 270 Dongan Road, Shanghai, 200032, People's Republic of China. wangqifeng19821982@126.com.

ORCID-Profile: Peng Qi

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Qi, P., Sun, Y., Pang, Y., Liu, J., Cai, X., Huang, S., Xu, Q., Wang, Q., & Zhou, X. (2025). Diagnostic Utility of a 90-Gene Expression Assay (Canhelp-Origin) for Patients with Metastatic Cancer with an Unclear or Unknown Diagnosis. Molecular Diagnosis & Therapy. https://doi.org/10.1007/s40291-024-00746-6

Vancouver

Qi P, Sun Y, Pang Y, Liu J, Cai X, Huang S, et al. Diagnostic Utility of a 90-Gene Expression Assay (Canhelp-Origin) for Patients with Metastatic Cancer with an Unclear or Unknown Diagnosis. Molecular Diagnosis & Therapy. 2025. doi:10.1007/s40291-024-00746-6

BibTeX
@article{Qi2025,
  author = {Qi, Peng and Sun, Yifeng and Pang, Yue and Liu, Jing and Cai, Xu and Huang, Shenglin and Xu, Qinghua and Wang, Qifeng and Zhou, Xiaoyan},
  title = {Diagnostic Utility of a 90-Gene Expression Assay (Canhelp-Origin) for Patients with Metastatic Cancer with an Unclear or Unknown Diagnosis},
  journal = {Molecular Diagnosis & Therapy},
  year = {2025},
  doi = {10.1007/s40291-024-00746-6}
}
Kostenlos starten →